21:52 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Actinium reports Phase II data for Actimab-A in AML

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) reported preliminary data from 13 evaluable patients ages 60 and older with newly diagnosed acute myelogenous leukemia (AML) who were unable to tolerate induction therapy in the Phase II portion of...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Actimab-A: Phase II started

Actinium began an open-label, U.S. Phase II trial to evaluate 2 uCi/kg/fraction doses of Actimab-A given at day 1 and 7 in about 53 patients ages >60. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y....
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Actimab-A: Additional Phase I/II data

Data from 14 previously untreated AML patients ages >=60 in the Phase I portion of an open-label, U.S. Phase I/II trial showed that 0.5, 1, 1.5 and 2 uCi/kg/fraction doses of Actimab-A plus low-dose cytarabine...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Actimab-A: Additional Phase I/II data

Additional data from 12 previously untreated AML patients >=60 in cohorts 1-3 of an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to 2 cases of complete remission with different degrees...
07:00 , Jun 8, 2015 |  BioCentury  |  Finance

ASCO's early returns

While discussions about value and incremental data from late-stage checkpoint inhibitors dominated this year's American Society of Clinical Oncology meeting in Chicago, it's clear that investors also were on the lookout for - and willing...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

Actimab-A regulatory update

FDA granted Orphan Drug designation to Actimab-A from Actinium to treat acute myelogenous leukemia (AML) in patients ages =60. The product -- actinium-225 attached to the anti- CD33 mAb lintuzumab (HuM195) -- is in Phase...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Actimab-A: Interim Phase I/II data

Interim data from 9 evaluable AML patients ages =60 in an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to a median overall survival (OS) of 5.4 months. In 7 of...
07:00 , Jun 30, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company said...
00:24 , Jun 25, 2014 |  BC Extra  |  Financial News

Actinium, Heron planning follow-ons

Late Tuesday, Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) and Heron Therapeutics Inc. (NASDAQ:HRTX) proposed follow-ons, but neither company disclosed how many shares they plan to issue or how much they expect to raise. Actinium's follow-on is underwritten...
01:49 , Dec 27, 2012 |  BC Extra  |  Financial News

Actinium raises $5.1M ahead of reverse-merger

Actinium Pharmaceuticals Inc. (Newark, N.J.) raised $5.1 million through the sale of about 9.3 million units in the first close of a bridge financing. Each unit comprises a share, a 120-day warrant to purchase a...